Long-term outcomes of modified 2-stage IPAA have not yet been evaluated, according to Dr Stefan Holubar (Cleveland Clinic Foundation, OH, USA) [1]. The modified 2-stage approach is defined as completion proctectomy without loop ileostomy, whereas the 3-stage approach includes completion proctectomy with loop ileostomy. For this study, 223 participants from the Adult Pouch Registry who underwent modified 2-stage IPAA between 1983 and 2019 were matched with 223 participants who underwent 3-stage IPAA. The primary outcome was pouch survival, defined by permanent diversion, pouch excision, and conversion to a Kock pouch.
Long-term pouch survival outcomes were similar between participants who underwent modified 2-stage or 3-stage IPAA (95.5% vs 93.2%; P=0.32; see Figure). However, 3-stage participants had a shorter postoperative length of hospital stay than modified 2-stage participants (5 vs 8 days; P<0.001). Also, a numerically but not significantly higher complication rate was reported in the modified 2-stage arm (17.0% vs 12.1%; P=0.09). Functional outcomes were mostly similar for the investigated approaches. The number of stools per 24 hours was 7 in both groups. Similarly, the proportion of participants requiring seepage protection at night did not significantly differ between the 3-stage and modified 2-stage arm (29.7% vs 24.6%; P=0.31). Participant satisfaction levels were comparable.
Figure: Kaplan-Meier curve for pouch survival (matched pairs) [1]
Dr Holubar said that modified 2-stage IPAA may be an alternative for patients with limited options. However, he emphasised that the modified 2-stage approach should only be performed by experienced surgeons in high-volume centres. Moreover, the eligible patient profile for modified 2-stage IPAA is highly selective. “Patients should display minimal pouch tension, 3 or lower on a scale from 1 to 10, have perfect betadine leak tests prior to anastomosis, and perfect endoscopic leak tests after anastomosis. Also, the physiology of the patient needs to fit the procedure.”
- Holubar S, et al. Modified 2-stage vs. 3-stage ileal pouch-anal anastomosis result in equivalent long-term functional outcomes and pouch survival: A matched-pair analysis. OP13, ECCO 2022, 16–19 February.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Similar results for different corticosteroid tapering protocols in UC Next Article
Segmental colectomy beneficial over total colectomy in Chrohn’s disease »
« Similar results for different corticosteroid tapering protocols in UC Next Article
Segmental colectomy beneficial over total colectomy in Chrohn’s disease »
Table of Contents: ECCO 2022
Featured articles
Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis
Novel Treatment Modalities
Guselkumab shows encouraging safety and efficacy in ulcerative colitis
Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease
Mirikizumab efficacious for active ulcerative colitis
Risankizumab more efficacious in colonic than in ileal Crohn’s disease
Guselkumab plus golimumab promising combination for ulcerative colitis
Combined endpoint may support personalised medicine in ulcerative colitis
Filgotinib seems promising for perianal fistulising Crohn’s disease
Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis
Upadacitinib counters extraintestinal manifestations in ulcerative colitis
Deucravacitinib does not meet primary endpoint for ulcerative colitis
Head-to-Head Comparisons
Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease
Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis
Subcutaneous infliximab versus subcutaneous vedolizumab in IBD
Vedolizumab outperforms anti-TNF in biologic-naïve ulcerative colitis
Short-Term and Long-Term Treatment Results
Ozanimod treatment shows maintained response in ulcerative colitis
Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease
Vedolizumab first approved therapy for chronic pouchitis
VEDOKIDS: Vedolizumab seems effective in paediatric IBD
Primary endpoint of 5-hydroxytryptophan for fatigue in IBD not met
Specific Therapeutic Strategies
Positive outcomes with therapeutic drug monitoring during infliximab maintenance therapy
Segmental colectomy beneficial over total colectomy in Chrohn’s disease
Modified 2-stage ileal pouch-anal anastomosis versus 3-stage alternative
Similar results for different corticosteroid tapering protocols in UC
Miscellaneous Topics
Lessons from the COVID-19 pandemic for IBD management
AI model distinguishes between histologic activity and remission in ulcerative colitis
Multi-Omic and dietary analysis of Crohn’s disease identifies pathogenetic factors
Novel classification system for perianal fistulising Crohn’s disease
Vaccination tool associated with improved vaccination coverage in IBD
Comparable safety profiles of biological therapies in elderly patients with IBD
Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease
RESTORE-UC: No better outcomes with FMT superdonors than with autologous stools
Related Articles
April 14, 2020
Pipeline of IBD drugs
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com